(0.18%) 5 109.11 points
(0.17%) 38 305 points
(0.20%) 15 960 points
(-1.05%) $82.97
(4.73%) $2.01
(0.06%) $2 348.60
(0.08%) $27.56
(4.02%) $959.20
(-0.18%) $0.933
(-0.26%) $11.00
(-0.45%) $0.797
(1.73%) $93.46
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 12.46%
@ $2.37
发出时间: 15 Feb 2024 @ 03:56
回报率: 58.98%
上一信号: Feb 15 - 03:02
上一信号:
回报率: -2.07 %
Live Chart Being Loaded With Signals
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer...
Stats | |
---|---|
今日成交量 | 397 289 |
平均成交量 | 1.24M |
市值 | 196.26M |
EPS | $0 ( 2024-02-28 ) |
下一个收益日期 | ( $-0.190 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.04 |
ATR14 | $0.00800 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Thomas Monica R. | Buy | 37 500 | Common Stock |
2024-03-20 | Avagliano Mark | Buy | 100 000 | Common Stock |
2024-03-20 | Umstead John W. V | Buy | 37 500 | Common Stock |
2024-03-18 | Umstead John W. V | Sell | 6 547 | Common Stock |
2024-02-12 | Malik Rajesh | Buy | 28 600 | Common Stock |
INSIDER POWER |
---|
72.69 |
Last 100 transactions |
Buy: 2 421 369 | Sell: 357 781 |
音量 相关性
G1 Therapeutics Inc 相关性 - 货币/商品
G1 Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $82.51M |
毛利润: | $75.32M (91.28 %) |
EPS: | $-0.930 |
FY | 2023 |
营收: | $82.51M |
毛利润: | $75.32M (91.28 %) |
EPS: | $-0.930 |
FY | 2022 |
营收: | $51.30M |
毛利润: | $47.55M (92.69 %) |
EPS: | $-3.38 |
FY | 2021 |
营收: | $31.48M |
毛利润: | $29.46M (93.60 %) |
EPS: | $-3.50 |
Financial Reports:
No articles found.
G1 Therapeutics Inc
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。